Phathom Pharmaceuticals (PHAT) Retained Earnings (2018 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Retained Earnings of -$1.5 billion for Q2 2026, down 6.91% year-over-year from -$1.6 billion in Q2 2025, and down 1.16% quarter-over-quarter from -$1.5 billion in Q1 2026.
Phathom Pharmaceuticals (PHAT) Retained Earnings (2018 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Retained Earnings for 9 consecutive years, with -$1.5 billion the latest figure, recorded in Q2 2026.
- In Q2 2026, Retained Earnings fell 6.91% year-over-year to -$1.5 billion; the TTM figure through Jun 2026 stood at -$1.5 billion (down 6.91% YoY), while the FY2025 annual figure was -$1.5 billion, down 17.52% from the prior year.
- Retained Earnings retreated to -$1.5 billion in Q2 2026 per PHAT's latest filing, from -$1.5 billion in the prior quarter.
- Across five years, Retained Earnings topped out at -$570.0 million in Q1 2022 and bottomed at -$1.5 billion in Q2 2026.
- Historically, Retained Earnings has averaged -$1.1 billion across 5 years, with a median of -$1.1 billion in 2024.
- Annual changes were most pronounced in 2024 — Retained Earnings sank 39.98% — and 2026, when it retreated 6.91%.
- Phathom Pharmaceuticals' Retained Earnings stood at -$727.1 million in 2022, then dropped by 27.73% to -$928.7 million in 2023, then sank by 36.0% to -$1.3 billion in 2024, then retreated by 17.52% to -$1.5 billion in 2025, then retreated by 3.23% to -$1.5 billion in 2026.
- Business Quant data shows PHAT's Retained Earnings at -$1.5 billion in Q2 2026, -$1.5 billion in Q1 2026, and -$1.5 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | Phathom Pharmaceuticals | 767.07 Mn | 581.73 Mn | 59.18 Mn | -1.53 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.53 Bn |
| Mar 31, 2026 | -1.51 Bn |
| Dec 31, 2025 | -1.48 Bn |
| Sep 30, 2025 | -1.46 Bn |
| Jun 30, 2025 | -1.43 Bn |
| Mar 31, 2025 | -1.36 Bn |
| Dec 31, 2024 | -1.26 Bn |
| Sep 30, 2024 | -1.19 Bn |
| Jun 30, 2024 | -1.10 Bn |
| Mar 31, 2024 | -1.01 Bn |
| Dec 31, 2023 | -928.69 Mn |
| Sep 30, 2023 | -849.12 Mn |
| Jun 30, 2023 | -805.87 Mn |
| Mar 31, 2023 | -764.91 Mn |
| Dec 31, 2022 | -727.09 Mn |
| Sep 30, 2022 | -672.05 Mn |
| Jun 30, 2022 | -620.96 Mn |
| Mar 31, 2022 | -570.04 Mn |
| Dec 31, 2021 | -529.37 Mn |
| Sep 30, 2021 | -493.54 Mn |